About Us

Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
My Watchlist
Indicators
Local Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Articles published by Amarin Corporation plc

< Previous 1 2 3 Next >
New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin To Present New Analyses Affirming Robustness of Data from REDUCE-IT and Additional Mechanisms of Action of Eicosapentaenoic Acid (EPA) at American Heart Association (AHA) Scientific Sessions 2025
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Reports Third Quarter 2025 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Issues Statement Supporting FDA’s Action to Revise Labeling for Fenofibrate Drugs Reinforcing a Lack of Cardiovascular Benefit
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin to Report Third Quarter 2025 Financial Results and Host Conference Call on October 29, 2025
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin and HLS Therapeutics Collaborate on Presenting REDUCE-IT® and EPA Mechanistic Data at the Canadian Cardiovascular Congress
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Highlights Key Data Providing Mechanistic Insights into Eicosapentaenoic Acid (EPA) at ESC 2025
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
New REDUCE-IT® Analyses Presented at ESC 2025 Include Data Showing VASCEPA®/VAZKEPA® (Icosapent Ethyl) Therapy Resulted in 9% Fewer Total Hospitalizations & Reduces Cardiovascular Disease Risk in Certain High-Risk Patient Subgroups
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
New Analyses from REDUCE-IT® and EPA Mechanistic Data to be Presented at the European Society of Cardiology (ESC) Congress 2025
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Reports Second Quarter 2025 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin to Report Second Quarter 2025 Financial Results and Host Conference Call on July 30, 2025
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Announces Exclusive License and Supply Agreement with Recordati to Commercialize VAZKEPA® (Icosapent Ethyl) in Europe
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Reports First Quarter 2025 Financial Results
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Regains Compliance with Nasdaq Minimum Bid Price Requirement
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Confirms Effective Date for 1-For-20 ADS Ratio Change
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Appoints JEC Capital Partners’ Michael Torok to Board of Directors
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Highlights Recent Data Presented at ACC.25 Evaluating Mechanistic Effects of Eicosapentaenoic Acid (EPA) in Lp(a)-Enriched Plasma and in Combination with GLP-1 Agonist
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
New Research Exploring Mechanistic Benefits of Eicosapentaenoic Acid (EPA) In Vitro on Lipoprotein(a) [Lp(a)] Oxidation and on Protein Expression in Endothelial Cells in Combination with GLP-1 Receptor Agonist to be Presented at the American College of
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Reports Fourth Quarter Financial Results & Business Update and Announces Important Corporate Action
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Marks Key Milestone for VASCEPA®/VAZKEPA® (Icosapent Ethyl) -- Publication of Post Hoc Analysis of REDUCE-IT in Journal of the American Heart Association Reports Benefit on Top of Cholesterol Lowering
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Receives National Reimbursement for VAZKEPA® in Austria
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin to Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 12, 2025
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Receives National Reimbursement for VAZKEPA® in Italy
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Appoints Peter Fishman Chief Financial Officer
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Investigators to Present New REDUCE-IT Subanalysis of VASCEPA®/VAZKEPA® (icosapent ethyl) in Patients With and Without Coronary Artery Disease History and Mechanistic Data on Eicosapentaenoic Acid (EPA) at the American Heart Association’s (AHA) Annual
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Reports Third Quarter 2024 Financial Results and Provides Business Update
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Amarin Announces Two Upcoming Investor Events
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
Research Highlighting the Clinical Impact of VASCEPA®/VAZKEPA (icosapent ethyl) in Patients with Diabetes and High Cardiovascular Risk and the Anti-Lp(a) Oxidation Mechanistic Effect of Eicosapentaenoic Acid (EPA) to be Presented at the 60th Annual
From Amarin Corporation plc
Via GlobeNewswire
Tickers AMRN
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.